Get in Touch

Start Referring Patients Today. Prevent AMD vision loss with remote monitoring. Fill out the form below to get started.
Doctor Ophthalmic Staff
Retina Specialist Comprehensive Ophthalmologist Optometrist
Retina Specialty Comprehensive Ophthalmology Optometry Technician Lead Technician Scribe Front Office Management Unknown
By Email By Phone
Internet Print Word of Mouth Other


Latest News

New Study Shows ForeseeHome Helps Maintain Your Vision for Years to Come

June 2022

The Analysis of the Long-Term Outcomes of ForeseeHome Remote Telemonitoring (ALOFT) study was initiated by doctors at five large clinics to determine how well ForeseeHome, along with the doctor’s regular care plan, performed in maintaining good vision for years after treatment is initiated for wet age-related macular degeneration (AMD). This is the first evidence of the long-term value of the of the ForeseeHome AMD Monitoring Program in a real-world setting and was published in the medical journal Ophthalmology Retina.

ALOFT looked at all patients referred to the Notal Vision Monitoring Center from five eye care clinics over a 10-year period. In total, 2,123 patients were followed for an average of 3.1 years. Out of the 3,334 eyes monitored, there were 285 eyes that converted to wet AMD. Patients in the study tested on the ForeseeHome device an average of 5.2 times per week, and that did not change over the course of the study.

The results of the study were truly astonishing. At conversion to wet AMD, 84% of patients lost less than one line of vision compared to baseline when they started with ForeseeHome. This means that most patients had 20/40 vision or better at conversion to wet AMD. 20/40 or better vision is the benchmark because it is the vision standard for driving (in most states) and the vision needed to easily perform many day-to-day tasks.

The ForeseeHome data is in stark contrast to data reported by the American Academy of Ophthalmology’s IRIS® Registry, a comprehensive eye disease database. Their data shows that only 34% of patients (who were not monitored with ForeseeHome) had 20/40 or better vision at wet AMD diagnosis. Furthermore, the ALOFT study found that 84% of all the patients monitored with ForeseeHome maintained their 20/40 or better vision for years after conversion to wet AMD with treatment.

Many of you often ask us, “Will testing regularly with the ForeseeHome device really help me maintain my ability to see and function normally if I convert to wet AMD?” According to the new ALOFT study data, we can confirm that yes, it will very likely do just that!

If you enjoy reading medical journals like we do, click the link below.

Read the ALOFT Study

Click Here

Related News

View Latest News
View Latest News